Detalhe da pesquisa
1.
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Int J Cancer
; 153(7): 1413-1422, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37424386
2.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814222
3.
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
BMC Cancer
; 21(1): 936, 2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412605
4.
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
BMC Cancer
; 21(1): 932, 2021 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407800
5.
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol
; 161(2): 374-381, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637349
6.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol
; 163(1): 72-78, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412908
7.
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
Future Oncol
; 16(16): 1069-1081, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32374623
8.
Challenges of international oncology trial collaboration-a call to action.
Br J Cancer
; 121(7): 515-521, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378784
9.
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Oncologist
; 24(11): e1102-e1107, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30936377
10.
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Gynecol Oncol
; 154(3): 531-538, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31227223
11.
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Gynecol Oncol
; 154(1): 29-37, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31130288
12.
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma.
Lancet Oncol
; 24(5): 419-420, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080221
13.
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
Gastric Cancer
; 21(3): 473-480, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28815316
14.
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers.
Med J Aust
; 209(8): 354-355, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30138578
15.
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Cochrane Database Syst Rev
; 3: CD011044, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29557103
16.
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Int J Gynecol Cancer
; 27(5): 900-906, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28498256
17.
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Br J Cancer
; 114(5): 505-9, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26867157
18.
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Int J Gynecol Cancer
; 24(5): 857-64, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24844219
19.
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
Int J Gynecol Cancer
; 24(5): 865-73, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24844220
20.
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Transl Oncol
; 43: 101914, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417292